The new cells prevented the onset of diabetes in an animal model of the disease bringing personalized cell therapy for diabetes closer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully-functional pancreatic cells. The new cells produced insulin in response to changes in glucose levels, and, when transplanted into mice, the cells protected the animals from developing diabetes in a mouse model of the disease.
The new study, published in Nature Communications, also presents significant advancements in cellular reprogramming technology, which will allow scientists to efficiently scale up pancreatic cell production and manufacture trillions of the target cells in a step-wise, controlled manner. This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
“Our results demonstrate for the first time that human adult skin cells can be used to efficiently and rapidly generate functional pancreatic cells that behave similar to human beta cells,” says Matthias Hebrok, PhD, director of the Diabetes Center at UCSF and a co-senior author on the study. “This finding opens up the opportunity for the analysis of patient-specific pancreatic beta cell properties and the optimization of cell therapy approaches.”
In the study, the scientists first used pharmaceutical and genetic molecules to reprogram skin cells into endoderm progenitor cells—early developmental cells that have already been designated to mature into one of a number of different types of organs. With this method, the cells don’t have to be taken all the way back to a pluripotent stem cell state, meaning the scientists can turn them into pancreatic cells faster. The researchers have used a similar procedure previously to create heart, brain, and liver cells.
After another four molecules were added, the endoderm cells divided rapidly, allowing more than a trillion-fold expansion. Critically, the cells did not display any evidence of tumor formation, and they maintained their identity as early organ-specific cells.
The scientists then progressed these endoderm cells two more steps, first into pancreatic precursor cells, and then into fully-functional pancreatic beta cells. Most importantly, these cells protected mice from developing diabetes in a model of disease, having the critical ability to produce insulin in response to changes in glucose levels.
“This study represents the first successful creation of human insulin-producing pancreatic beta cells using a direct cellular reprogramming method,” says first author Saiyong Zhu, PhD, a postdoctoral researcher at the Gladstone Institute of Cardiovascular Disease. “The final step was the most unique—and the most difficult—as molecules had not previously been identified that could take reprogrammed cells the final step to functional pancreatic cells in a dish.”
Sheng Ding, PhD, a senior investigator in the Roddenberry Stem Cell Center at Gladstone and co-senior author on the study, adds, “This new cellular reprogramming and expansion paradigm is more sustainable and scalable than previous methods. Using this approach, cell production can be massively increased while maintaining quality control at multiple steps. This development ensures much greater regulation in the manufacturing process of new cells. Now we can generate virtually unlimited numbers of patient-matched insulin-producing pancreatic cells.”
The Latest on: Personalized cell therapy
via Google News
The Latest on: Personalized cell therapy
- ThermoGenesis Announces Corning's Commercial Launch of the X-SERIES® Cell Processing Products Developed by ThermoGenesison June 23, 2020 at 11:03 am
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, ...
- Personalized Medicine Market 2020 Worldwide Opportunities, Driving Forces, COVID-19 Impact Analysis, Future Potential 2028on June 21, 2020 at 11:05 pm
What is Personalized Medicine Market?Advancements in science and technology are fluctuating, especially the way we ...
- Genomic profiling in renal cell carcinomaon June 19, 2020 at 7:15 am
Genomic profiling of renal cell carcinoma has demonstrated the clinical relevance of several genetic alterations in different disease subtypes. Pal and colleagues discuss the prognostic and predictive ...
- Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell Mediaon June 18, 2020 at 6:07 pm
A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient ...
- ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Researchon June 18, 2020 at 4:00 am
ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer ...
- Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapieson June 17, 2020 at 4:57 pm
The cancer cell therapies available today are made by tweaking a patient’s own immune cells to better recognize and fight the disease. Orca Bio is ...
- Vineti launches new Alliance Network -- and announces a collaboration with Mavens -- to deliver integrated solutions for cell and gene therapieson June 16, 2020 at 5:48 pm
Vineti, Inc., the leading provider of cloud-based Personalized Therapy Management (PTM) software for advanced therapies, announced a new Vineti Alliance Network to deliver integrated solutions to ...
- Personalized Meds Will Drive Sector-Wide Bioprocessing Innovationon June 16, 2020 at 12:00 pm
Precision medicine is extremely disruptive to the model of a blockbuster molecule produced in centralized facilities so that flexible tech and non-traditional sites will play a greater role.
- Global Cell Therapy Market, Therapy Price, Dosage Clinical Trials 2027on June 16, 2020 at 2:31 am
Over a period of time, cell therapy has emerged as next growth frontier for the pharmaceutical companies involved the research and development of innovative therapies for the treatment of simple to ...
- High throughput technology drives developments in personalized cancer immuno-therapieson June 14, 2020 at 5:46 pm
Developing effective cancer immunotherapies for solid tumors can be extremely challenging, primarily because they have physical barriers the immune response must overcome. 3T Biosciences identifies ...
via Bing News